Q2 2025

Filed Aug 7, 2025 · 10-Q · 38 days after period end · 0001558370-25-010789

Q2 2025 · 10-Q

Revenue

$1.78M

−35.8% vs Q2 2024

Net Income

-$15.43M

N/M vs Q2 2024

EPS Diluted

-$0.13

N/M vs Q2 2024

Operating Income-$18,408,000N/M

Operating Cash Flow

Same quarter

Metric	Q2 2025	Q2 2024	Q2 2023	Q2 2022
Revenue	$1.78M	$2.77M	$1.87M	$1.53M
Net Income	-$15.43M	-$10.99M	-$29.57M	-$20.53M
EPS Diluted	-$0.13	-$0.15	-$0.42	-$0.31

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR